Journals / Medicine Science / 2018 / Cilt: 7 - Sayı: 2

The protective effect of coumaric acid against cisplatin-induced ototoxicity in rats

Pages
373–377
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results showed that PCA protects the cochlea from ototoxic effect of cisplatin.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cis-diammineedichloroplatinum (cisplatin) is a chemotherapeutic agent used for the treatment of several types of cancer.
📊
Key Findings & Data:To the best of our knowledge, no previous research has investigated the protective effect of PCA against cisplatin-induced ototoxicity. 28 Wistar rats were used.
💡
Conclusion & Impact:The results showed that PCA protects the cochlea from ototoxic effect of cisplatin.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Cis-diammineedichloroplatinum (cisplatin) is a chemotherapeutic agent used for the treatment of several types of cancer. However, severe side-effects such as ototoxicity, nephrotoxicity and neurotoxicity restrict its use. p-Coumaric acid (PCA) is a phenol class compound obtained from various plants in nature such as grape, carrot and tomato and from beverages such as tea and beer. It was shown to have antioxidant and free radical scavenging, anti-inflammatory and neuroprotective effects. The purpose of this study was to perform a biochemical and histopathological evaluation of the protective efficacy of PCA in ototoxicity induced with cisplatin in rats. To the best of our knowledge, no previous research has investigated the protective effect of PCA against cisplatin-induced ototoxicity. 28 Wistar rats were used. The animals were randomly divided into four groups of seven members each. No drug was administered to the rats in the control group, while the cisplatin group received a single intraperitoneal dose of 10 mg/kg cisplatin. PCA was administered to the PCA group rats by the intraperitoneal route for three days at a dose of 100 mg/kg. In the cisplatin+PCA group, intraperitoneal PCA at 100 mg/kg was administered one hour after injection of 10 mg/kg intraperitoneal cisplatin for three consecutive days. Rats were sacrificed 24 h after the final drug administration. The cochlear tissues were removed and MDA levels, GPx and SOD activities were measured to evaluate the oxidative stress status and histopathological evaluation was performed to reveal cochlear damage. The results showed that PCA protects the cochlea from ototoxic effect of cisplatin. PCA is a reliable agent that provides significant biochemical and histopathological protection against cisplatin-induced ototoxicity in rats.

🔖

Cite This Article

AKDEMİR, F. N. E., GÖZELER, M. S., YILDIRIM, S., KIZILTUNÇ, A., ESER, G., AŞKIN, S. (2018). The protective effect of coumaric acid against cisplatin-induced ototoxicity in rats. Medicine Science, Cilt: 7 - Sayı: 2, 373–377. https://ajindex.com/articles/277617

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Toplu Y, Sapmaz E, Parlakpinar H, et al. The Effect of Dexpanthenol on Ototoxicity Induced by Cisplatin. Clin Exp Otorhinolaryngol. 2016;9(1):1420. Nagy JL, Adelstein DJ, Newman CW, et al. Cisplatin ototoxicity: the importance of baseline audiometry. Am J Clin Oncol. 1999;(28):305-8.
  2. Laurell G, Bagger-Sjoback D. Dose-dependent inner ear changes after I.V. administration of cisplatin. J Otolaryngol. 1991;(20):158-67.
  3. Khynriam, D, Prasad. S.B. Changes in glutathione-related enzymes in tumorbearing mice after cisplatin treatment. Cell Biol. Toxicol. 2002;(18) 349-58.
  4. Kruidering M, Van de Water B, de Heer E, et al. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J. Pharmacol. Exp. Ther. 1997;(280):638-49.
  5. Kopelman J, Budnick AS, Sessions RB, et al. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope. 1988;(98):858-64.
  6. Casares C, Ramírez-Camacho R, Trinidad A, et al. Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. Eur. Arch. Otorhinolaryngol. 2012;(269):2455-9.
  7. Guven M, Bozkurt AA, Akman T. Neuroprotective effect of p-coumaric acid in rat model of embolic cerebral ischemia. Iran J Basic Med Sci 2015;(18):356-63.
  8. Donald E. Paglia, William N. Valentina. Studies on the quantitative characterization of erythrocyte glutathione peroxidase. J. Lab. & Clin Med. 1967;158- 69. Ohkawa H, Ohiski N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbutric acid reaction. Anal Biochem. 1979;(95):351-8.
  9. Sun Yi, Larry W. Oberley, Ying Li. A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988;(3413):497-500.
  10. Huang T, Cheng AG, Stupak H, et al. Oxidative stress-induced apoptosis of cochlear sensory cells: otoprotec¬tive strategies. Int J Dev Neurosci. 2000;(23):259-70.
  11. Yumusakhuylu AC, Yazici M, Sari M, et al. Protective role of resveratrol against cisplatin induced ototoxicity in guinea pigs. Int J Pediatr Otorhinolaryngol. 2012;(3):404-8.
  12. Lopez-Gonzalez MA, Guerrero JM, Rojas F, et al. Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res. 2000;(28):73–80.
  13. Kalkanis JG, Whitworth C, Rybak LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope. 2004;(114):538-42.
  14. Erdem T, Bayindir T, Filiz A, et al. The effect of resveratrol on the prevention of cisplatin